David A. Siegel Arcellx, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Arcellx, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 5,600 shares of ACLX stock, worth $359,856. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,600
Previous 4,500
24.44%
Holding current value
$359,856
Previous $375,000
13.6%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ACLX
# of Institutions
223Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$281 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$241 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$226 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$224 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$214 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.82B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...